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Neurocutaneous disorders are multisystem diseases affecting skin, brain, and other 
organs. Epilepsy is very common in the neurocutaneous disorders, affecting up to 90% 
of patients with tuberous sclerosis complex (TSC) and Sturge–Weber syndrome (SWS), 
for example. The mechanisms underlying the increased predisposition to brain hyperex-
citability differ between disorders, yet some molecular pathways overlap. For instance, 
the mechanistic target of rapamycin (mTOR) signaling cascade plays a central role in sei-
zures and epileptogenesis in numerous acquired and genetic disorders, including several 
neurocutaneous disorders. Potential routes for target-specific treatments are emerging 
as the genetic and molecular pathways involved in neurocutaneous disorders become 
increasingly understood. This review explores the clinical features and mechanisms of 
epilepsy in three common neurocutaneous disorders—TSC, neurofibromatosis type 1, 
and SWS.
Keywords: seizure, epilepsy, neurocutaneous disorder, tuberous sclerosis complex, neurofibromatosis, Sturge–
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wHAT iS A NeUROCUTANeOUS DiSORDeR?
Neurocutaneous disorders are a heterogeneous group of genetic disorders characterized by abnor-
malities of the cutaneous and nervous systems. Tuberous sclerosis complex (TSC), neurofibroma-
tosis type I (NF1), and Sturge–Weber syndrome (SWS) are prototypical neurocutaneous disorders 
in which genetic mutations in pathways regulating cell growth cause developmental dysfunction of 
the brain, skin, and other organs. Clinically, these neurocutaneous disorders differ significantly, but 
certain similarities also exist. Namely, all neurocutaneous disorders are congenital, affect several 
organs, are associated with learning or developmental problems, persist lifelong, are currently 
uncorrectable, and are optimally managed with a multidisciplinary approach in which neurolo-
gists, oncologists, educational specialists, neuropsychologists, and other therapists work together 
to monitor for potential complications of the respective disease and maximize abilities. In addition, 
there is now emerging evidence of some overlap in the cellular signaling pathways in these disorders 
(1–3). Epilepsy, defined as the condition of recurrent, unprovoked seizures, is a common feature of 
many of the neurocutaneous disorders. This chapter reviews aspects of the clinical presentation and 
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management of epilepsy in TSC, NF1, and SWS and focuses on 
possible mechanisms of seizures and epilepsy in each disorder. 
Emphasis is placed on why epilepsy is so prevalent in these 
conditions.
MeCHANiSMS OF SeiZUReS  
AND ePiLePSY
A seizure is an episode of transient neurological dysfunction due to 
abnormal firing of neurons. Epilepsy is the condition of recurrent, 
unprovoked seizures. An epilepsy syndrome involves a specific 
seizure type(s) plus other features such as age of onset, electro-
encephalographic (EEG) findings, genetics/natural history, and 
responsiveness to particular drugs. A seizure occurs when there 
is an imbalance between excitation (E) and inhibition (I) in one 
or more areas of the brain. An E/I imbalance can manifest at the 
level of subcellular signaling pathways, ion channels, synapses, 
or neuronal networks. Any molecular, cellular, or structural 
pathology that increases excitation or decreases inhibition can 
generate a seizure (4). For example, enhanced activity or function 
of excitatory glutamatergic synapses or their receptor subtypes 
[i.e., alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) or N-methyl-d-aspartate (NMDA)] or decreased 
activity or function of inhibitory gamma-aminobutyric acid 
(GABA)-ergic neurons or receptors would favor seizure genera-
tion. Similarly, dysfunction of sodium or calcium channels (often 
excessive current flow through these channels) or diminished 
function of potassium channels may predispose to hyperexcit-
ability and seizures.
Epilepsy or the process by which epilepsy develops (epilep-
togenesis) also entails E/I imbalance but other cellular pathologies 
can also be involved, such as structural or circuit rearrangements, 
inflammation, or disrupted epigenetic regulation. Therefore, the 
mechanisms underlying a seizure and those leading to epilepsy 
overlap but epileptogenesis also involves additional processes. 
Though admittedly oversimplified, the concept of an imbalance 
between excitation and inhibition is helpful when considering 
seizure and epilepsy mechanisms in neurocutaneous disorders, 
and pathophysiological changes can be considered at each of 
these levels of neuronal function (4, 5).
TUBeROUS SCLeROSiS COMPLeX
Clinical Features of TSC
Tuberous sclerosis complex is a multiorgan system disorder 
occurring at a frequency of about 1 in every 5,000 births. The 
disorder is caused by a mutation in TSC1 or TSC2, which are 
tumor repressor genes controlling the activity of the mechanistic 
target of rapamycin (mTOR) signaling pathway (formerly called 
mammalian target of rapamycin), discussed further below. 
Overactivity of the mTOR pathway accelerates mRNA translation 
and causes excessive protein synthesis and cell growth, leading to 
the formation of benign tumors in several organs and giving rise 
to the distinctive clinical features of TSC. For this reason, TSC 
is considered the prototypical “mTOR-opathy.” Full diagnostic 
criteria for TSC have been published recently (6, 7). Classic skin 
findings include hypopigmented macules (ash-leaf spots) and 
facial angiomatoses. In addition, patients with TSC commonly 
have cardiac rhabdomyomas (often present at birth with subse-
quent involution) and renal angiomyolipomas (develop over time 
and frequently lead to renal insufficiency in childhood or adult-
hood). Here, we focus on central nervous system abnormalities 
in TSC that may lead to seizures.
Three major neuropathological findings characterize TSC 
(Figure 1A1). First, hamartomas (tubers) of widely variable size 
and number form in the cerebral cortex, often at the gray–white 
matter junction. Tubers are composed of a mixture of abnormal 
cells, including dysplastic, immature, cytomegalic neurons and 
glia, all lacking a normal lamination pattern. Importantly, tubers 
do not tend to expand or grow. Although tubers are considered to 
be static lesions, some dynamic features have been documented 
and tubers may appear to become more prominent over time 
due to interval myelination and other factors (8, 9). Tubers are 
extremely epileptogenic and can produce one or more seizure 
foci in the brain. A seizure can arise from the tuber itself or from 
perituberal cortex adjacent to the tuber (10, 11). Tubers differ in 
their epileptogenicity, even within the same patient. The precise 
localization of the epileptogenic focus is critical for planning 
tuber resection surgery. The number, volume, and possibly loca-
tion of tubers correlate to some extent with the patient’s level of 
intellectual impairment and cognitive dysfunction (12, 13). For 
example, tubers located in the temporal lobe are associated with 
a high incidence of autism (14, 15). Second, abnormal neuronal 
and glial tissue, called subependymal nodules (SENs), can arise in 
the periventricular regions. SENs can transform into subependy-
mal giant cell astrocytomas (SEGAs). Due to their location near 
the foramen of Monro, SEGAs can cause acute blockage of 
cerebrospinal fluid flow at that site, leading to hydrocephalus 
(Figure 1A2). However, owing to their cellular composition and 
location deep in the brain, SEGAs are not epileptogenic. Third, 
radially oriented heterotopias occur within white matter, consist-
ent with disordered neuronal migration; these heterotopias have 
been associated with behavioral problems and may also contrib-
ute to epileptogenesis (Figure 1A1) (16). Together, these three 
neuropathological features account for the major age-dependent 
neurologic complications of TSC, namely, epilepsy (90%), autism 
(25–50%), and intellectual disability (40–80%). The common 
occurrence of neuropsychological deficits in TSC, including 
learning disability, attention deficits, spatial memory problems, 
aggressive behaviors, anxiety, and sleep disruption, has given rise 
to the term TAND (tuberous sclerosis-associated neuropsychiat-
ric disorders) (17). Optimal management of patients with TSC 
must address TAND as well as epilepsy.
epilepsy in TSC
Seizures are extremely common in TSC, affecting up to 90% of 
patients (18). In 63% of TSC patients with epilepsy, the seizures 
appear in the first year of life; 80% of seizures begin before 3 years 
of age and 70% eventually become refractory to drugs. The sei-
zures may be focal, multifocal, infantile spasms, or a combination 
of these or other seizure types. Infantile spasms are a seizure type, 
FigURe 1 | examples of brain MRi scans in patients with 
neurocutaneous disorders. (A) 8-year-old boy with tuberous sclerosis 
complex. (A1) Axial fluid attenuation inversion recovery (FLAIR) and (A2) 
coronal contrast-enhanced T1-weighted images show multiple cortical/
subcortical, partially calcified mixed FLAIR-hyper/hypointense tubers in the 
right front parietal lobes (arrows, A1), FLAIR-hyperintense migration lines 
(triangle, A1), and a homogeneously enhancing, round subependymal giant 
cell astrocytoma within the right foramen of Monro (arrow, A2). (B) 
16-year-old girl with neurofibromatosis type 1. (B1) Axial FLAIR and T1 
post-contrast images showing a large expansile lesion centered at the right 
precentral gyrus (*) indicating a low-grade glioma. (B2) Axial T2 FLAIR image 
reveals focal areas of signal intensity (arrows) in the right globus pallidus and 
putamen and similar but to a lesser extent on the contralateral side, 
representing nonspecific unidentified bright objects. (C) 21-month-old boy 
with Sturge–Weber syndrome. (C1) Axial T1-weighted post-contrast image 
showing left hemisphere atrophy with prominent choroid plexus glomus 
(arrow). (C2) Coronal T1-weighted post-contrast image with occipital-parietal 
leptomeningeal enhancement (arrow).
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a subtype of epileptic spasms occurring in the first year of life, 
and often occur as part of the electroclinical syndrome, West syn-
drome. Focal seizures may be isolated or occur in association with 
infantile spasms, and most cases of infantile spasms also include 
other seizure types. The incidence of infantile spasms is extremely 
high, affecting approximately one-third of children with TSC (18, 
19). In about 5% of children with TSC, spasms continue or develop 
after 2 years of age, making this a very common semiology (20). 
With multiple tubers comprising potential seizure foci, it is not 
surprising that focal or multifocal seizures are present in TSC, 
but the frequent occurrence of infantile spasms has not been 
explained adequately. It is difficult to categorize infantile spasms 
solely as generalized or focal seizures, as both occur, even in TSC. 
Thus in the case of TSC, the common final output—spasms—can 
obviously be produced by focal or multifocal lesions. Abnormal 
mTOR function may be another explanation for infantile spasms, 
but mTOR dysfunction is seen in only a subset of the numerous 
etiologies of infantile spasms, so mTOR pathway dysfunction is 
not required for infantile spasms to occur.
Earlier seizure onset portends a less favorable outcome with 
regard to neuropsychiatric and developmental function (17). 
In TSC, the interaction between epilepsy and neuropsychiatric 
sequelae is complex, compounded by adverse effects of the 
therapies used to treat epilepsy. As opposed to classic epileptic 
encephalopathies in which seizures themselves cause cognitive 
impairment beyond the etiology, in TSC it is the molecular 
etiology—mTOR overactivation—that probably drives both the 
epilepsy and the encephalopathy/TAND (21).
The treatment of seizures in TSC involves conventional 
antiseizure drugs as well as non-pharmacological interventions 
such as the ketogenic diet, vagus nerve stimulation, or in some 
cases, surgical resection of the epileptogenic tubers (13, 22, 23). 
The percentage of patients with drug-refractory epilepsy in TSC 
(~70%) is much higher than the percentage of drug-refractoriness 
among patients with epilepsy in general (~30%) (24). Early surgi-
cal resection is recommended if a dominant tuber is identified, 
i.e., an area from which the majority of seizures appear to origi-
nate, but the presence of multiple tubers often makes it difficult 
to localize the most epileptogenic one. This identification may be 
aided by the use of positron emission tomography (PET) scans, 
which can localize brain regions with abnormal metabolism even 
in the absence of a structural lesion (25). The goal of surgery is 
palliation of seizure burden, though cognition can also improve 
after the targeted resection of an epileptogenic tuber (26). 
A meta-analysis of 229 patients in 13 studies concluded that 59% 
of patients were seizure free after surgery (27).
For infantile spasms in children with TSC, vigabatrin is the 
first choice medication, rather than adrenocorticotropic hormone 
or corticosteroids as used more commonly for infantile spasms 
due to other etiologies. The vigabatrin response rate is between 
73% and 96% (28). It is unknown why vigabatrin works so well 
in TSC-associated infantile spasms. The therapeutic benefit could 
be related to vigabatrin’s main mechanism of action—inhibition 
of GABA transaminase, leading to increased availability of 
the inhibitory neurotransmitter GABA at the synapse—or to 
vigabatrin-induced decrease in mTOR activation (29). [However, 
the situation may not be so simple, as mTOR is upregulated by 
the excessive GABA present when the gene for succinic semialde-
hyde dehydrogenase is knocked out in mice (mimicking human 
SSADH deficiency) (30).] Since infants with TSC have such a 
high risk for developing infantile spasms, a novel approach is to 
treat infants who have epileptiform abnormalities on EEG (but 
no documented seizures) prophylactically with vigabatrin before 
spasms begin (31, 32). This approach is being tested in an ongoing 
European multicenter trial called EPISTOP.
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Mechanistic target of rapamycin inhibition could comprise a 
rational, disease-modifying treatment for seizures in TSC (2, 9, 
13, 23). mTOR inhibitors such as rapamycin (sirolimus) have been 
found to decrease the size of kidney angiomyolipomas and SEGAs 
(33) and are being trialed for seizures as well (23). Another mTOR 
inhibitor, everolimus, has shown benefit for seizures in TSC in 
a phase I/II clinical trial (34). In that trial, seizure frequency 
decreased by at least 50% in 12 of 20 participants and the median 
decrease in seizures was 73% in 17 of the 20 patients; in addition, 
there was a decrease in seizure duration and improved quality 
of life on several parent-reported measures. A recent phase III 
double-blind randomized study of 366 TSC patients with treat-
ment-resistant focal-onset seizures (EXIST-3) compared placebo 
versus low- or high-dose everolimus (35). The median reduction 
in seizure frequency was 40% in those receiving high-dose everoli-
mus and 28% in subjects receiving low-dose everolimus, both 
statistically significant compared with a 15% seizure reduction in 
the placebo group. Notably, children with infantile spasms were 
excluded from these studies. These results raise the possibility that 
mTOR inhibition decreases seizure frequency in TSC by targeting 
the molecular defect, representing a unique, disease-modifying 
approach. This and other therapies are urgently needed for epi-
lepsy in TSC, emphasizing the importance of understanding the 
mechanisms of epileptogenesis in this disorder (36).
Molecular Basis of TSC—Overactivation  
of the mTOR Pathway
Tuberous sclerosis complex arises de novo in approximately 
70–80% of cases; in the remainder of cases, inheritance is auto-
somal dominant or due to genetic mosaicism. The disorder is 
caused by a mutation in one of the tumor suppressor genes, TSC1 
or TSC2. TSC1, located on chromosome 9, encodes the protein 
hamartin. TSC2, located on chromosome 16, encodes the protein 
tuberin. Under normal circumstances, hamartin and tuberin act 
together as a dimer to inhibit the mTOR signaling pathway and 
constrain cell growth and differentiation (37). mTOR is a serine/
threonine kinase that acts as a central regulator of cell growth, 
differentiation, proliferation, and migration. Mutation of either 
TSC1 or TSC2 leads to the clinical features of TSC, which are 
variably expressed due to incomplete penetrance of the mutated 
gene. It is thought that tuber/hamartoma development requires 
“two hits,” whereby a germline mutation in one allele of TSC1 
or TSC2 is complemented by a second somatic mutation in the 
other allele, leading to cell growth derangement and hamartoma 
formation (38). Overall, TSC2 mutations confer worse seizures 
and cognition than TSC1 mutations (20, 39, 40).
The mTOR signaling pathway begins at the cell membrane, 
where receptors respond to growth factors and nutrient/energy 
molecules (Figure 2). Phosphatidylinositol triphosphate 3-kinase 
(PI3K) activates protein kinase B (AKT) which is a serine/
threonine-specific protein kinase and potent pro-survival and 
pro-oncogenic protein. AKT directly phosphorylates TSC2 and 
inhibits its function. TSC2 inactivation by AKT reduces Ras 
homolog enriched in brain (Rheb), a small GTPase that is a mem-
ber of the Ras (rat sarcoma) superfamily. Overexpression of Rheb 
due to a TSC1 or TSC2 mutation leads to increased mTOR acti-
vation and excessive cell growth and proliferation. These effects 
are blocked by rapamycin, which inhibits the mTOR pathway 
by binding directly to mTOR (mTOR complex 1 or mTORC1), 
thereby decreasing phosphorylation of downstream mTOR 
effectors (41, 42). These downstream effectors include two key 
regulators of protein translation, ribosomal S6-kinase (S6K) and 
eukaryote initiation factor 4E binding protein 1 (4E-BP1). The 
loss of TSC1 or TSC2 function leads to selective hyperactivation 
of the mTOR cascade, resulting in mTOR-dependent increased 
phosphorylation of S6K and 4E-BP1 proteins (43). Therefore, 
these gene mutations provide a plausible mechanism to account 
for the characteristic giant cells (cytomegaly) in TSC. Inhibition 
of this cascade by mTOR inhibitors results in growth suppression 
and restricted cell size.
Aside from its control of cell growth and survival, mTOR is 
also involved in synaptic plasticity, learning and memory (44). 
Long-term potentiation (LTP), a process whereby repeated acti-
vation of a neural pathway strengthens the connections between 
neurons, is considered to be a cellular correlate of learning and 
memory. mTOR activation is involved in the late phase form of 
LTP that is dependent on protein synthesis. The impairment of 
LTP by seizures is a candidate mechanism for cognitive impair-
ment in epilepsy (45, 46). In TSC1 conditional knockout mice, 
TSC1+/−, the LTP deficit is partially reversed by NMDA receptor 
antagonists, and it has been suggested that LTP impairment is 
due to overactivation of the mTOR pathway or NMDA receptors 
(i.e., by seizures) (47, 48). Likewise, in TSC2+/− mice, rapamycin 
improves synaptic plasticity (LTP) and reduces behavioral defi-
cits (49).
In addition to its pivotal role in the pathogenesis of TSC, 
mTOR dysfunction also plays a role in other neurologic disorders, 
both genetic (hemimegalencephaly, focal cortical dysplasia) and 
acquired (temporal lobe epilepsy, traumatic brain injury) (37, 48, 
50–52). mTOR’s central action on cell growth regulation occurs 
in other neurocutaneous disorders as well, as discussed below for 
NF1 and SWS.
epilepsy Mechanisms in TSC
In TSC, the mechanisms of E/I imbalance leading to seizure 
generation and epileptogenesis are complex and multifactorial, 
related to both the dysfunction of the mTOR signaling pathway 
(abnormal cellular excitation) and the neuropathological sub-
strates (hyperexcitable circuits) (53, 54). TSC pathophysiology 
may be summarized as follows: abnormal molecules in abnormal 
cells form abnormal circuits, together leading to increased seizure 
propensity and epileptogenesis (55). This summary statement 
emphasizes the involvement of pathophysiological factors at mul-
tiple levels of brain function. In TSC, numerous features could 
contribute to the propensity for epilepsy by altering E/I balance, 
including altered cerebral cortical architecture, astrocyte prolif-
eration, calcification, altered vascular anatomy, edema, altered 
neurotransmitter receptor expression, and cell proliferation and 
death (Figure 3) (42).
Favoring excess excitation, glutamate receptors in dysplastic 
neurons and giant cells have increased expression of NMDA recep-
tor subunits NR2B and NR2D (in newer nomenclature, GluN2B 
and GluN2D) and the neuronal glutamate transporter EAAC1 (56). 
In TSC1+/− mice, there is persistent, mTOR-dependent selective 
FigURe 2 | Molecular pathways involved in three common neurocutaneous disorders— tuberous sclerosis complex (TSC), neurofibromatosis type 1, 
and Sturge–weber syndrome. As elaborated in the text, this diagram indicates unique sites of dysfunction as well as interactive and overlapping pathways that 
might serve as target-specific interventions.
FigURe 3 | Possible contributors to cellular hyperexcitability and seizures in three common neurocutaneous disorders—tuberous sclerosis complex 
(TSC), neurofibromatosis type 1 (NF1), and Sturge–weber syndrome (SwS).
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functional upregulation of the NMDA receptor subunit GluN2C, 
specifically in cortical layer IV neurons that are critical for thalamo-
cortical integration of excitatory activity; this receptor subtype 
mediates excessive current through NMDA channels and enhances 
recurrent excitation and seizure propensity; furthermore, seizure 
generation is blocked by GluN2C antagonists (57). Tubers resected 
from children with TSC have a selective increase in the expression 
of AMPA receptor subunits GluR1 and GluR2 in dendrites of 
dysplastic neurons compared with normal neurons, suggesting 
that increased calcium permeability engendered by these recep-
tor subunit alterations could promote epileptogenesis (58). Mice 
lacking TSC1 also exhibit abnormally long excitatory postsynaptic 
currents and epileptic discharges, like human tubers (59).
Favoring decreased inhibition, tubers have lower levels of the 
GABA synthetic enzyme glutamate decarboxylase 65, the vesicu-
lar GABA transporter VGAT, and GABAA receptor subunits α1 
and α2 (56). In cortical specimens from patients with TSC, the 
number of GABAergic interneurons is decreased, consistent 
with diminished and aberrant local inhibition (60). Excessive 
depolarizing GABA responses in tuberal neurons were blocked 
by bumetanide, a compound that inhibits the ion transporter 
sodium-potassium-chloride cotransporter 1 (NKCC1) (61, 62). 
Microtransplantation of cortical membranes from TSC patients 
into Xenopus oocytes revealed a lack of expected maturation of 
both GABAA receptor function (delayed transition to hyperpolar-
izing action) and a persistently elevated ratio of NKCC1 to the 
potassium-chloride cotransporter 2 (KCC2, whose expression is 
more prominent beyond the neonatal stage and is responsible for 
the hyperpolarizing action of GABA receptor activation); also, 
AMPA receptor subunit expression (GluR1/GluR2 ratio) was 
increased compared to non-TSC control tissue that did undergo 
developmental maturation, suggesting a pattern of cerebral dys-
maturity in TSC (63). Ion channel dysfunction might also cause 
hyperexcitability in TSC—in astrocytes of TSC1-deficient mice, 
there is decreased expression of potassium inward rectifier chan-
nels (Kir2.1 and Kir 6.1), limiting the passage of hyperpolarizing 
current (64). Collectively, these observations suggest that differ-
ent tuber components possess different molecular profiles that 
could alter the E/I balance in favor of excitation and predispose 
to seizures.
In addition to molecular alterations, mTOR overactivity, via 
TSC1 and TSC2 mutation, leads to structural aberrations in neu-
rons and dendrites and their growth. The soma size and dendrite 
size and density of hippocampal pyramidal cells are perturbed 
by the loss of a single copy of TSC1 (65). Additional mechanisms 
that may play a role in seizure predisposition in TSC include 
somatic and dendritic hypertrophy, aberrant basal dendritic 
structure, and enlargement of axon tracts. These changes lead to 
increased synaptogenesis and recurrent circuit formation (66). 
E/I imbalance may be promoted by mTOR-dependent repres-
sion of inhibitory input onto excitatory hippocampal pyramidal 
neurons, resulting in excitatory positive feedback (67). Attesting 
to the role of the mTOR pathway and its inhibition in disorders 
other than TSC, in a rodent model of temporal lobe epilepsy, 
rapamycin reduces the sprouting of mossy fiber axons that in part 
underlies hyperexcitability in the hippocampal dentate gyrus and 
may underlie epilepsy progression (68). Furthermore, rapamycin 
directly augments inhibition by increasing potassium channel 
(Kv1.1) expression (69) and decreases excitation by reducing 
the surface expression of AMPA receptors (70). Rapamycin 
also reduces the duration of epileptiform bursts induced by the 
GABAA receptor antagonist, bicuculline (71).
Animal models of TSC, created by deletion or knockout of 
TSC1 or TSC2 in certain cell types, have provided considerable 
insight into mechanisms by which seizures and epilepsy occur in 
TSC, as indicated by several experimental observations already 
discussed. Mice with conditional knockout of glial fibrillary 
acidic protein (GFAP), a marker of glial cells, have increased 
mTOR activity and increased SK6 leading to enhanced epilep-
togenicity. Importantly, brains of these knockout animals have 
no tubers (72). Therefore, epilepsy in these mice occurs without 
requiring the presence of a tuber or other macroscopic structural 
lesion, suggesting that alteration of the mTOR pathway itself is 
sufficient to generate seizures. The function of the glutamate 
transporters GLT and GLAST is decreased in astrocytes of these 
mice (73). The result is altered glutamate homeostasis with 
excessive extracellular and synaptic glutamate levels, leading to 
excitotoxicity via increased excitatory postsynaptic potentials 
and increased NMDA receptor activation, which increase seizure 
propensity. Acute seizures activate the mTOR pathway transiently 
(74), whereas status epilepticus leads to chronic mTOR elevation 
(75). There is also evidence of increased inflammatory markers 
such as IL-1β in GFAP knockout mice, and treatment with anti-
inflammatory drugs leads to decreased seizures and increased 
survival (76). Timing of mTOR inhibition may be important—
early treatment with rapamycin decreases mTOR activation, 
decreases glial proliferation, increases GLT1 expression, prevents 
epilepsy, and increases survival. Late rapamycin treatment, given 
after the mice have already developed spontaneous seizures, is 
also beneficial in decreasing seizure frequency and increasing 
survival (72). It remains a mystery why patients with TSC have 
such a high predilection to infantile spasms. The lack of animal 
models of infantile spasms hinders exploration of the underlying 
pathophysiology (77). In the “multiple-hit” model of infantile 
spasms, high-dose rapamycin delivered in daily pulses for 3 days 
ameliorates spasm occurrence (78); this is not a TSC model per se, 
rather one that mimics symptomatic spasms as a consequence 
of brain injury induced by three toxins. These results implicate 
the mTOR pathway as a possible treatment target in symptomatic 
infantile spasms and emphasize the possible effectiveness of 
pulse mTOR inhibition as opposed to continuous rapamycin 
administration.
NeUROFiBROMATOSiS TYPe 1
Clinical Features of NF1
Neurofibromatosis type 1, the most common neurocutane-
ous disorder, occurs in approximately 1 in 3,000 births (79). 
Inheritance is autosomal dominant and the mutations are de 
novo in about half the cases. The diagnosis of NF1 is clinical, 
based on consensus criteria (80), and confirmation with genetic 
testing is available but usually not necessary (81). Disease 
manifestations are quite diverse, even within a family, related to 
variable penetrance of the mutation. Characteristic findings are 
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hyperpigmented skin markings or café-au-lait macules (which 
typically develop in the first 2  years of life), axillary freckling, 
disease-specific Lisch nodules (hamartomas of the iris), optic 
pathway gliomas, and neurocognitive deficits. NF1 patients are 
also at risk to develop multiple benign and malignant Schwann 
cell neoplasms such as tumors of the peripheral nerve sheath, 
gliomas, pheochromocytoma, gastrointestinal stromal tumors, 
and other cancers including breast cancer in young women and 
leukemia (82). Neurofibromas, the hallmark of the disease, are 
benign nerve sheath tumors of two types, dermal (which can 
be cutaneous or subcutaneous) or plexiform. Both types may 
grow and cause pain and disfigurement; however, only plexiform 
neurofibromas can undergo malignant transformation into a 
malignant peripheral nerve sheath tumor, an aggressive spindle-
cell sarcoma with poor prognosis (83). Optic pathway gliomas 
are very common, affecting up to 15% of children with NF1, 
the majority presenting before 7  years of age. Gliomas of the 
hemispheres, brainstem, or cerebellum can also occur, which are 
mostly pilocytic or diffuse astrocytomas (Figure 1B1). In addi-
tion to gliomas, central nervous system lesions in NF1 frequently 
include T2-hyperintensities on MRI scan, known as “unidentified 
bright objects” (UBOs) (Figure 1B2) (84). Autopsy studies have 
demonstrated that UBOs are vacuolar changes in myelin sheaths 
with dysplastic glial proliferation, often seen in the cerebellum, 
basal ganglia, subcortical white matter, and thalamus (85). The 
etiopathogenesis of UBOs is unknown; their presence may be 
associated with poorer cognition, but the data remains conflicted 
(86, 87). Intriguingly, UBOs often disappear by adulthood and 
their role in nervous system dysfunction is unclear (88). Also, 
cortical malformations, in the form of disordered cortical archi-
tecture, have been documented (85, 89).
Cognitive deficits in NF1 tend to be mild or moderate and 
include learning problems in more than half the patients, and 
these can be significant enough to affect academic performance 
and quality of life. Although no specific learning disability is 
characteristic of NF1, common deficits affect visual-spatial and 
visual motor abilities, executive function, verbal and nonverbal 
language, fine and gross motor coordination, and attention 
(90–92). Sleep disorders and anxiety are very common. Migraine 
headaches occur in up to 33%, autism in 15%, and epilepsy in 
6–10% (93). Megalencephaly, manifesting as macrocephaly, is 
due to increased white matter volume (94). Other organ systems 
often involved in NF1 include skeletal (long bone dysplasia, 
scoliosis) and vascular (blood vessel stenosis, especially the renal 
artery; aneurysms; hypertension).
epilepsy in NF1
While epilepsy is much less common in NF1 than in TSC, its 
incidence of 6–10% is still considerably greater than that of epi-
lepsy in the general population (0.5%). Seizures in NF1 tend to 
have focal onset and commonly generalize secondarily (95–97). 
It is thought that seizures in NF1 arise from the numerous focal 
lesions that comprise the disorder, namely, tumors and malforma-
tions of cortical development (Figure 1B1). Thus, seizure occur-
rence requires neuroimaging, even if previous neuroimaging was 
normal. The relationship of UBOs to seizures is controversial, 
but most studies have concluded that UBOs are not associated 
with seizures (84, 96). Seizures in NF1 are often relatively easy to 
control with one or more conventional antiseizure drugs; surgical 
resection of offending lesions is sometimes pursued (98). Surgery 
has been most successful for temporal lobe gliomas (93).
Molecular Basis of NF1—Ras 
Overactivation
The NF1 gene on chromosome 17 encodes neurofibromin, a 
large cytoplasmic tumor suppressing protein. Neurofibromin, a 
GTPase-activating protein that suppresses the proto-oncogene 
Ras, is highly expressed in neurons and glia, especially oligo-
dendrocytes. Neurofibromin ordinarily inhibits Ras activity by 
catalyzing the hydrolysis of GTP-bound Ras to GDP-bound Ras 
(converts the proto-oncogene p21-Ras from an active form to an 
inactive form), thereby preventing tumor formation (Figure 2) 
(37, 99). In NF1, the lack of neurofibromin leads to unopposed Ras 
(GTPase) activity, causing released control of downstream signals 
involved in cell growth and differentiation, such as mitogen-acti-
vated protein kinase (MAPK, also known as extracellular-signal 
regulated kinase or ERK) and mTOR. Activation of Ras leads to 
enhanced activation of Ras-PI3K, MAPK, and mTOR. Therefore, 
NF1 is considered a “Ras-opathy.” Neurofibromin controls mTOR 
via a common biochemical pathway with tuberin (100). In that 
sense, the molecular pathways in TSC and NF1 share some 
common features. mTOR overactivation has been demonstrated 
in NF1-associated tumors (99). However, the degree of mTOR 
activation in NF1 is modest compared to TSC, and it is not known 
how significant a role mTOR dysfunction plays in NF1 or NF1-
associated seizures (3). Neurofibromin also positively regulates 
cyclic adenosine monophosphate (cAMP), and increased cAMP 
levels are associated with decreased cell growth (92).
In NF1, cognitive deficits appear to be related to synaptic 
dysfunction as a consequence of signaling dysfunction of 
Ras-ERK, cAMP, and dopamine homeostasis rather than to a 
macroscopic structural lesion. In mice with targeted disruption 
of NF1 (heterozygous null mutations, NF1+/−), Schwann cells 
have increased Ras activation and increased growth rate. These 
mice have cognitive impairments that parallel many human NF 
deficits in visuospatial learning, working memory, attention, and 
motor skills (101). Despite a lack of structural brain abnormali-
ties, these mutant mice demonstrate several deficits in cognitive 
function. NF1+/− mice have impaired LTP, constituting a cellular 
basis for their impaired ability to perform hippocampus-based 
tasks involving spatial learning and memory (102). Furthermore, 
the cognitive deficits in NF1 are thought to arise from increased 
GABAergic signaling and can be reversed in animal models by 
pharmacologically inhibiting Ras-ERK activity with statin drugs 
(e.g., lovastatin, simvastatin) (103, 104). Studies in Drosophila 
homozygous for null NF1 gene mutations revealed a linkage 
between cAMP generation and neurofibromin as the underly-
ing cause for neurobehavioral manifestations in NF1 (105), 
later confirmed in mammalian species (106). In these studies, 
decreased cAMP generation due to reduced levels of functional 
neurofibromin resulted in olfactory learning deficits. However, 
the role of cAMP in human cognitive dysfunction in NF1 patients 
remains less clear and further investigations are required. Lastly, 
reduced dopamine levels in the striatum have been described in 
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NF1+/− mice and correction of the dopamine defect resulted in 
improved cognition whereas Ras inhibition was ineffective (107). 
Due to those multiple mechanisms underlying neurobehavioral 
deficits, it is not surprising that clinical trials of lovastatin in 
patients have had variable success (108). Some benefits in work-
ing memory and verbal memory were found in a recent 14-week 
randomized trial of lovastatin versus placebo (109).
epilepsy Mechanisms in NF1
Neurofibromin plays important roles in multiple aspects of 
cortical development, including synaptic plasticity, learning and 
memory, neurotransmitter phenotype, and synapse formation 
(92). However, it is unclear why brains of individuals with NF1 
are hyperexcitable and predisposed to seizures, and this topic 
is rarely discussed in the literature (110, 111). Possibilities are 
admittedly speculative and comprise the spectrum of patho-
physiologies that disrupt the E/I balance. Of possible relevance 
to seizure mechanisms, it was found that GABA release and levels 
are enhanced in NF1+/− mice, a result of loss of neurofibromin 
leading to unrestrained ERK signaling and enhanced synaptic 
GABA release (104). While this finding was used to explain the 
impaired cognition, learning, and LTP of NF1+/− mice, decreased 
rather than increased GABA levels would be more consistent with 
a predisposition to epilepsy. However, augmented GABA release 
strategically limited to local inhibitory circuits could theoretically 
enhance excitability.
Ion channels are also receiving increasing attention in NF1, 
both in the peripheral nervous system, where enhanced pain 
perception is a common clinical problem, and in the central 
nervous system, related to abnormal LTP and cognition (112). 
Calcium channel opening is enhanced, and calcium currents 
are increased in hippocampal neurons in NF1+/− mice (113), 
which would increase excitability and neurotransmitter release. 
Dysfunction of a variety of ion channels (e.g., sodium, potas-
sium, hyperpolarization-activated cyclic nucleotide-gated) has 
been reported in different brain regions and NF models (112, 
114), but no consistent pattern has emerged to put forward a 
unified hypothesis about cortical hyperexcitability or seizures. 
In peripheral nociceptors, several sodium channel isoforms 
(NaV1.1, NaV1.7, NaV1.8) have increased expression and activity 
in NF1+/− mice, leading to hyperexcitability (115). These findings 
may have relevance to central neurons and circuits, a topic ripe 
for investigation in terms of epilepsy mechanisms in NF. There is 
no published information as to whether NF1+/− mice have altered 
susceptibility to seizures induced by standard experimental 
methods (e.g., bicuculline, kindling).
STURge–weBeR SYNDROMe
Clinical Features of SwS
Sturge–Weber syndrome, with an estimated incidence of 1 in 20,000 
live births, is a sporadically occurring neurocutaneous disorder 
characterized by vascular malformations of the brain, skin, and 
eyes (116). The clinical hallmarks are facial angiomas (port-wine 
birthmarks), malformations of leptomeningeal blood vessels, and 
ocular angiomas causing glaucoma. Children born with a facial 
port-wine birth mark in the region of the forehead, temple, and 
upper eyelid have a greatly increased risk of also having brain or 
eye involvement. The cerebral vascular malformations are typi-
cally unilateral (on the same side as the port-wine birthmark) but 
can also occur bilaterally, which confers a worse prognosis (117). 
Clinical manifestations include recurrent strokes and stroke-like 
episodes that can lead to hemiparesis, visual field defects, cogni-
tive deterioration, and developmental delays involving language 
and behavior (116). Most infants develop fairly normally for 
some period of time prior to the onset of seizures. Children may 
manifest with early handedness or a gaze preference. Seizures 
most commonly present in the first year of life (118). Along with 
the capillary-venous leptomeningeal malformations, cortical 
malformations such as focal cortical dysplasia or polymicrogyria 
can also be seen (119, 120). The cerebral atrophy, calcification, 
and clinical deficits can be progressive, particularly in infants 
and young children. Later problems can include specific learning 
disabilities, attention deficit disorder, and hormone deficiencies 
(e.g., growth hormone, thyroid hormone) (121, 122).
epilepsy in SwS
Epilepsy occurs in 72% of SWS cases with unilateral cerebral 
involvement and 90% or more of those with bilateral involvement 
(117, 123). Seizures usually have a focal onset with secondary 
generalization. Although seizures often begin in the first year of 
life and generally by 2 years of age, about 10% can begin later in 
childhood, adolescence, or adulthood. The seizures commonly 
occur in clusters or as status epilepticus, with relatively long 
periods between bouts (124). The prolonged seizures in SWS are 
thought to worsen cognitive function (125). The combination of 
seizures very early in life (before 6 months of age), and extensive 
brain pathology portends a poor outcome. Seizures in SWS can 
be progressive as brain atrophy advances, leading to refractory 
epilepsy. Seizures sometimes respond to anticonvulsants such 
carbamazepine or oxcarbazepine; levetiracetam, also used com-
monly in SWS, can be effective at times but is associated with 
more frequent side effects (126). Topiramate and valproic acid 
are useful third-line agents. While topiramate should always be 
used with caution owing to the possibility that it can exacerbate 
glaucoma, children with SWS do not appear to be at increased 
risk for topiramate-associated glaucoma. In SWS, topiramate-
associated glaucoma is an adverse effect seen more commonly, 
but not exclusively, in adults (127). Metabolic approaches such 
as the ketogenic or modified Atkins diet can be effective (128). 
Surgical options for refractory epilepsy include focal resection or 
hemispherectomy (129). Aspirin has been advocated to reduce 
stroke occurrence (130). mTOR inhibitors have not been studied 
in SWS. The high incidence of seizures in SWS raises the prospect 
that prophylactic treatment prior to the onset of seizures might 
improve developmental outcome, and clinical trials of this idea 
are needed (131).
Molecular Basis of SwS—Abnormal Blood 
vessel Formation
Sturge–Weber syndrome is caused by a post-zygotic somatic 
mosaic mutation of GNAQ, a gene that is critical for blood vessel 
TABLe 1 | epilepsy in common neurocutaneous disorders.
Disorder gene 
mutation
Abnormal 
protein product
epilepsy 
frequency
Most common 
seizure types
Molecular/cellular mechanism of 
epilepsy
Mechanism-
specific therapy?
Tuberous sclerosis 
complex (TSC)
TSC1 or  
TSC2
Hamartin or 
tuberin
70–90%  – Focal onset, may 
generalize
 – Infantile spasms
 – mTOR overactivation
 – Cortical dysgenesis and tubers
 – K channels
 – GABA
 – Vigabatrin
 – mTOR inhibitors
Neurofibromatosis (NF) 
type 1
NF1 Neurofibromin 6–10%  – Focal onset, may 
generalize
 – Ras overactivation
 – Cortical malformations and dysgenesis
 – Neurofibromin role in cortical 
development
 – Ras inhibitors
Sturge–Weber 
syndrome (SWS)
GNAQ Gαq (GTPase) 70–90%  – Focal onset, may 
generalize, especially 
in clusters
 – Status epilepticus
 – Abnormal blood vessel development
 – Cerebral calcifications
 – Neuronal loss
 – Astrogliosis
 – Cortical dysgenesis
 – ASDs
 – ASA
TSC, tuberous sclerosis complex; NF, neurofibromatosis; GNAQ, gene for guanine nucleotide-binding protein (G protein), subunit alpha, q polypeptide; Gαq, guanine nucleotide-
binding protein (G protein), subunit alpha, q polypeptide; GTP, guanosine-5′-triphosphate; GABA, gamma-aminobutyric acid; mTOR, mechanistic target of rapamycin; Ras, rat 
sarcoma; ASD, antiseizure drug; ASA, acetyl salicylic acid (aspirin).
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development (132). Interestingly, GNAQ mutations are found in 
individuals who have the full spectrum of SWS with skin, eye, and 
brain involvement as well as in patients with isolated port-wine 
birth marks and no brain or eye involvement. Mutations earlier 
in development are presumed to be associated with more severe 
manifestations; an animal model needs to be developed to test this 
hypothesis. GNAQ codes for Gαq, the alpha subunit of a hetero-
trimeric G protein that activates downstream pathways including 
the ERK and mTOR pathways (Figure 2). Most recent evidence 
suggests that endothelial cells in the capillary malformations are 
particularly enriched in GNAQ mutations (133) but the precise 
mechanisms by which the mutation in endothelial cells results in 
the vascular malformations of SWS are not known. Expression 
of angiogenesis factors, such as vascular endothelial growth 
factor, hypoxia-inducible factor α1 (134), and fibronectin (135) 
is altered, and these factors likely play an important role in the 
pathophysiology. For example, Elfn1 (extracellular-leucine-rich 
repeat fibronectin domain 1) is a gene enriched in hippocampal 
GABAergic interneurons that helps to recruit metabotropic glu-
tamate receptors (e.g., mGluR7) to the presynaptic membrane; 
mutant mice with Elfn1 knocked out develop seizures (136, 137).
epilepsy Mechanisms in SwS
The mechanism of epileptogenesis in SWS is uncertain, but 
abnormal blood vessel development undoubtedly figures promi-
nently in the neuropathology and epilepsy pathogenesis (138). 
The clinical consequences of SWS are in part related to abnormal 
draining veins leading to venous stasis and congestion, which 
decreases regional perfusion and eventually causes hypoxic brain 
injury with neuronal loss and gliosis. Cortical malformations 
such as polymicrogyria with inherent circuit dysfunction also 
contribute to epilepsy pathogenesis (119). Seizures appear to 
originate in the cortex adjacent to the leptomeningeal angioma 
(139). Ictal single positron emitted computed tomography studies 
have demonstrated that prolonged seizures exacerbate perfusion 
deficits and may increase the risk of stroke (140). Diseased brain 
tissue shows decreased blood flow interictally and increased or 
decreased blood flow during a seizure. Positron emission tomog-
raphy (PET) scans, which measure glucose uptake and therefore 
correlate with neuronal activity, have demonstrated interictal 
hypermetabolism in children with SWS, possibly indicating 
areas of incipient cortical dysfunction; these observations have 
implications for surgical planning (141). Fluorodeoxyglucose-
PET and clinical studies show that if seizures are controlled for a 
prolonged period, glucose metabolism and neurodevelopmental 
status can improve (142). Increased vascular permeability from 
the leptomeningeal malformations likely leads to calcium leakage 
across the blood–brain barrier. While calcium itself is probably 
not epileptogenic, it certainly represents a marker for areas of 
cortical dysfunction.
An animal model would facilitate understanding of epilepsy 
pathogenesis in SWS, and efforts to create such a model are under-
way (143). However, there are several challenges to generating 
a model of a disorder with somatic mosaic mutations involving 
gain-of-function. The mutant gene must be expressed in the rel-
evant cells and body structures only, a gene knockout approach is 
not applicable, and the developmental timing of the post-zygotic 
mutation is unknown. Nevertheless, molecular approaches to 
model creation using cell culture, mice, and other systems such as 
zebrafish should afford insights into seizure mechanisms as a con-
sequence of endothelial cell maldevelopment (143). Continuing 
the theme already discussed for TSC and NF1, alterations in 
specific signaling molecules and pathways may engender hyper-
excitable circuits in SWS, with mTOR dysfunction occupying a 
central location in the molecular pathways controlling numerous 
cell differentiation and migration (144). However, a role of mTOR 
in epileptogenesis in SWS has not been defined.
CONCLUSiON
Clinical and mechanistic aspects of epilepsy in TSC, NF1, and 
SWS are summarized in Table 1.
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Targeted therapies are emerging from increased molecular 
understanding of neurocutaneous disorders, based on both 
unique molecular pathways for each syndrome and commonali-
ties among syndromes [i.e., mTOR dysfunction (2, 3, 110)]. Clues 
to the pathophysiology of epilepsy in TSC, NF1, and SWS may 
arise from the observation that in each disorder, seizures have 
a focal onset, focusing attention on mechanisms altering the 
E/I balance at discrete sites of seizure initiation and subsequent 
spread. Figure 3 lists some of the factors that may lead to neuronal 
hyperexcitability in these neurocutaneous disorders.
Other insights might be gleaned from the very rare cases in 
which more than one neurocutaneous syndrome exists in a single 
individual. For example, a child was reported with maternal 
inheritance of NF1 and paternal inheritance of TSC (145). This 
girl developed intractable epilepsy at age 5 years and felbamate 
was the only antiseizure drug that helped. Since felbamate’s main 
mechanism of action is NMDA receptor antagonism and since 
NMDA downregulates the mTOR pathway, it was suggested that 
felbamate was acting specifically to dampen the mTOR pathway 
and reduce neuronal excitability. Such speculations are intrigu-
ing but need to be considered cautiously. A few patients with 
combined SWS and TSC have been reported, but none since the 
discovery of the somatic mutation causing SWS (146); it would 
be informative to better understand these dual mutations. There 
is no doubt, however, that epilepsy mechanisms in neurocutane-
ous disorders represent a vastly understudied topic that warrants 
concerted clinical and laboratory investigations. Indeed, epilepsy 
mechanisms may reveal new insights into the relationship 
between cognition, behavior, seizures, and other aspects of brain 
function in the neurocutaneous disorders (147).
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